Selejilin etkileşimleri

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (Amfetamin etiketi, Kontrendikasyonlar)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (Amfetamin ve dekstroamfetamin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS IOPIDINE 1% Ophthalmic Solution is contraindicated for patients receiving monoamine oxidase inhibitor therapy and for patients with hypersensitivity to any component of this medication or to clonidine. (Apraklonidin etiketi, Kontrendikasyonlar)

Taking, or within 14 days of stopping, a monoamine oxidase inhibitor (MAOI) [see Drug Interactions (7) ] . (Atomoksetin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. (Benzfetamin etiketi, Kontrendikasyonlar)

• Concomitant use of dextromethorphan, because of reported episodes of psychosis or bizarre behavior. (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

The use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. (Buspiron etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

Antihistamines are also contraindicated in the following conditions: Hypersensitivity to dexchlorpheniramine maleate or other antihistamines of similar chemical structure Monoamine oxidase inhibitor therapy (See Drug Interaction section) (Deksklorfeniramin etiketi, Kontrendikasyonlar)

• Concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions ( 7.1 )] . (Deksmetilfenidat etiketi, Kontrendikasyonlar)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Drug Interactions ]. (Dekstroamfetamin etiketi, Kontrendikasyonlar)

• Concomitant use of dextromethorphan, because of reported episodes of psychosis or bizarre behavior. (Selejilin etiketi, Kontrendikasyonlar)

• Concomitant use of dextromethorphan, because of reported episodes of psychosis or bizarre behavior. (Selejilin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result. (Dietilpropion etiketi, Kontrendikasyonlar)

Avoid use of diphenoxylate hydrochloride and atropine sulfate in patients who take MAOIs and monitor for signs and symptoms of hypertensive crisis (headache, hyperthermia, hypertension). (Difenoksilat ve atropin etiketi, İlaç etkileşimleri)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

…Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [ see Drug Interactions… (Doksilamin ve piridoksin etiketi, Kontrendikasyonlar)

Taking monoamine oxidase inhibitors (MAOIs). (Dötetrabenazin etiketi, Kontrendikasyonlar)

However, based on mechanism of action, the use of non-selective MAO inhibitors and linezolid should be avoided as there is a potential for increased blood pressure when taken with NORTHERA. (Droksidopa etiketi, İlaç etkileşimleri)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

Selective Serotonin Reuptake Inhibitors/Serotonin and Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs and MAO inhibitors [see Warnings and Precautions (5.7) ]. (Eletriptan etiketi, İlaç etkileşimleri)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

…coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension, pulmonary hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other… (Fendimetrazin etiketi, Kontrendikasyonlar)

• Concomitant use of other drugs in the monoamine oxidase inhibitor (MAOI) class or other drugs that are potent inhibitors of monoamine oxidase, including linezolid), because of an increased risk for hypertensive crisis [see Warnings and Precautions (5.1)]. (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

…cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (Fentermin etiketi, Kontrendikasyonlar)

…Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] With glaucoma [see Warnings and Precautions (5.3) ] With hyperthyroidism Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7) ] With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release… (Fentermin ve topiramat etiketi, Kontrendikasyonlar)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

Selective Serotonin Reuptake Inhibitors / Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during combined use of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [ see Warnings and Precautions (5.7) ]. (Frovatriptan etiketi, İlaç etkileşimleri)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of granisetron and other serotonergic drugs. (Granisetron etiketi, Uyarılar ve önlemler)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

• Concomitant use of other drugs in the monoamine oxidase inhibitor (MAOI) class or other drugs that are potent inhibitors of monoamine oxidase, including linezolid), because of an increased risk for hypertensive crisis [see Warnings and Precautions (5.1)]. (Selejilin etiketi, Kontrendikasyonlar)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (Karbamazepin etiketi, Kontrendikasyonlar)

Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa. (Karbidopa etiketi, Kontrendikasyonlar)

DUOPA is contraindicated in patients who are currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. (Karbidopa ve levodopa etiketi, Kontrendikasyonlar)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (Karbidopa, levodopa ve entakapon etiketi, Kontrendikasyonlar)

…because deaths have been reported in this age group [see Warnings and Precautions (5.1)]. patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Carbinoxamine Maleate Extended-Release Oral Suspension [see Warnings and Precautions (5.4)]. patients who are taking monoamine oxidase inhibitors (MAOI) [see Drug Interactions (7)]. (Karbinoksamin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or who have recently (within 2 weeks) taken a nonselective MAO inhibitor. (Levodopa etiketi, Kontrendikasyonlar)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

MAO Inhibitors ZELAPAR is contraindicated for concomitant use with other drugs in the MAOI class or other drugs that are potent inhibitors of monoamine oxidase (including linezolid, an oxazolidinone antibacterial, which also has reversible nonselective MAO inhibition activity) because of the increased risk for hypertensive crisis [see Contraindications (4) and… (Selejilin etiketi, İlaç etkileşimleri)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.7) and Drug Interactions (7.1) ] . (Lisdeksamfetamin etiketi, Kontrendikasyonlar)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Metamfetamin etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (Metildopa etiketi, Kontrendikasyonlar)

• Concomitant use of other drugs in the monoamine oxidase inhibitor (MAOI) class or other drugs that are potent inhibitors of monoamine oxidase, including linezolid), because of an increased risk for hypertensive crisis [see Warnings and Precautions (5.1)]. (Selejilin etiketi, Kontrendikasyonlar)

Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor because of the risk of hypertensive crisis [see Drug Interactions (7.1) ]. (Metilfenidat etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, avoid use in patients with hypertension or in patients taking monoamine oxidase inhibitors [see Drug Interactions ( 7.1 )] . (Metoklopramid etiketi, Uyarılar ve önlemler)

Avoid use of MAO inhibitors or linezolid with midodrine. (Midodrin etiketi, İlaç etkileşimleri)

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (Milnasipran etiketi, Kontrendikasyonlar)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] . (Naratriptan etiketi, İlaç etkileşimleri)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

…serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a non-selective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (ELDEPRYL), rasagiline (AZILECT), and olanzapine (Zydis) selegiline (ZELAPAR). (Selejilin etiketi, Uyarılar ve önlemler)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (Ondansetron etiketi, Uyarılar ve önlemler)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (Palonosetron etiketi, Uyarılar ve önlemler)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

• Concomitant use of dextromethorphan, because of reported episodes of psychosis or bizarre behavior. (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (Psödoefedrin etiketi, Uyarılar)

…serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a non-selective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (ELDEPRYL), rasagiline (AZILECT), and olanzapine (Zydis) selegiline (ZELAPAR). (Selejilin etiketi, Uyarılar ve önlemler)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (Rizatriptan etiketi, İlaç etkileşimleri)

Sarı kantaronun antidepresanlarla ve diğer serotonerjik ilaçlarla birlikte alınması serotonin sendromu riskini artırır. (NCCIH, St. John's Wort)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

Monoamine oxidase inhibitor therapy (See DRUG INTERACTIONS ). (Siproheptadin etiketi, Kontrendikasyonlar)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

SUNOSI is contraindicated in patients receiving concomitant treatment with monoamine oxidase (MAO) inhibitors, or within 14 days following discontinuation of monoamine oxidase inhibitor, because of the risk of hypertensive reaction [see Drug Interactions ( 7.1 )] . (Solriamfetol etiketi, Kontrendikasyonlar)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] . (Sumatriptan etiketi, İlaç etkileşimleri)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (Sumatriptan ve naproksen etiketi, İlaç etkileşimleri)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

• Taking monoamine oxidase inhibitors (MAOIs). (Tetrabenazin etiketi, Kontrendikasyonlar)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone). (Selejilin etiketi, Kontrendikasyonlar)

…serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a non-selective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (ELDEPRYL), rasagiline (AZILECT), and olanzapine (Zydis) selegiline (ZELAPAR). (Selejilin etiketi, Uyarılar ve önlemler)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

John’s wort or cyclobenzaprine (a tricyclic muscle relaxant). (Selejilin etiketi, Kontrendikasyonlar)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (Valbenazin etiketi, İlaç etkileşimleri)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

Qelbree is contraindicated in patients: receiving concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, because of an increased risk of hypertensive crisis [see Drug Interactions (7.1) ] . receiving concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic… (Viloksazin etiketi, Kontrendikasyonlar)

• May cause serotonin syndrome when used with antidepressants (5.2) (Selejilin etiketi, Uyarılar ve önlemler)

• Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. (Ziprasidon etiketi, Kontrendikasyonlar)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Dyskinesia ZELAPAR may potentiate dopaminergic side effects of levodopa and may cause dyskinesia or exacerbate preexisting dyskinesia. (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Monoamine oxidase inhibitors may result in increased hypotension. (Brimonidin etiketi, İlaç etkileşimleri)

Monoamine oxidase inhibitors may result in increased hypotension. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

Dyskinesia ZELAPAR may potentiate dopaminergic side effects of levodopa and may cause dyskinesia or exacerbate preexisting dyskinesia. (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

…of Adverse Reactions Due to Drug Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors… (Bupivakain etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (Butalbital ve parasetamol etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (Diazepam etiketi, İlaç etkileşimleri)

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines. (Difenhidramin etiketi, İlaç etkileşimleri)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (Disikloverin etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

…1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance,… (Droperidol etiketi, Uyarılar)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression. (Estazolam etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

…Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. (Glibenklamid etiketi, İlaç etkileşimleri)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Glimepirid etiketi, İlaç etkileşimleri)

…increase the susceptibility to and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory… (Glipizid etiketi, İlaç etkileşimleri)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (Glipizid ve metformin etiketi, Önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Drug Interactions MAO inhibitors should be used with caution in patients receiving hydralazine. (Hidralazin etiketi, İlaç etkileşimleri)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (İnsülin aspart etiketi, İlaç etkileşimleri)

…Degludec Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (İnsülin degludek etiketi, İlaç etkileşimleri)

…with LEVEMIR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (İnsülin detemir etiketi, İlaç etkileşimleri)

…Glargine-yfgn Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (İnsülin glarjin etiketi, İlaç etkileşimleri)

Clinically Significant Drug Interactions with LYUMJEV Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (İnsülin lispro etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Concomitant Use with MAO Inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (İzofluran etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Dyskinesia ZELAPAR may potentiate dopaminergic side effects of levodopa and may cause dyskinesia or exacerbate preexisting dyskinesia. (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines. (Klemastin etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (Klonazepam etiketi, İlaç etkileşimleri)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (Klorazepat etiketi, İlaç etkileşimleri)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (Kloroprokain etiketi, Önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Monoamine-oxidase inhibitors: Concomitant administration may potentiate the effects and toxicity of monoamine-oxidase inhibitors. (Kokain etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (Lidokain etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (Mepivakain etiketi, Uyarılar)

Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. (Metoprolol etiketi, İlaç etkileşimleri)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

…Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid,… (Nateglinid etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

Dyskinesia ZELAPAR may potentiate dopaminergic side effects of levodopa and may cause dyskinesia or exacerbate preexisting dyskinesia. (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Monoamine Oxidase Inhibitors (MAOI) Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly. (Prometazin etiketi, İlaç etkileşimleri)

…Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose… (Regüler insülin (insan) etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Dyskinesia ZELAPAR may potentiate dopaminergic side effects of levodopa and may cause dyskinesia or exacerbate preexisting dyskinesia. (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (Sevofluran etiketi, İlaç etkileşimleri)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (Süksinilkolin etiketi, İlaç etkileşimleri)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Baseline treatment with dopamine agonists or selegiline did not appear to increase the likelihood of experiencing orthostatic hypotension when treated with Tolcapone tablets. (Tolkapon etiketi, Önlemler)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (Selejilin etiketi, İlaç etkileşimleri)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (Selejilin etiketi, Uyarılar ve önlemler)

Drug Interactions Since the chemical structure of difenoxin hydrochloride is similar to meperidine hydrochloride, the concurrent use of MOTOFEN ® with monoamine oxidase inhibitors may, in theory, precipitate a hypertensive crisis. (Difenoksin ve atropin etiketi, İlaç etkileşimleri)

Entacapone can be taken concomitantly with a selective MAO-B inhibitor (e.g., selegiline). (Entakapon etiketi, Uyarılar)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (Glibenklamid ve metformin etiketi, İlaç etkileşimleri)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (Propranolol etiketi, İlaç etkileşimleri)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Repaglinid etiketi, İlaç etkileşimleri)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (Terbinafin etiketi, İlaç etkileşimleri)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (Triheksifenidil etiketi, İlaç etkileşimleri)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Zolmitriptan etiketi, Uyarılar ve önlemler)